Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

GPX4-IN-6 is a covalent inhibitor of glutathione peroxidase 4 (GPX4; IC50 = 130 nM).1 It inhibits the growth of MDA-MB-468, BT-549, and MDA-MB-231 breast cancer cells (IC50s = 12, 3.4, and 8 nM, respectively). GPX4-IN-6 (10 and 20 µM) increases lipid peroxidation and oxidized malondialdehyde (MDA) levels in MDA-MB-231 cells, an effect that can be prevented by ferrostatin-1 (Item No. 17729). It decreases mitochondrial volume and induces degradation of mitochondrial crests and outer membranes in MDA-MB-231 cells when used at a concentration of 20 µM. In vivo, GPX4-IN-6 (10 or 20 mg/kg per day) reduces tumor volume and weight, without affecting body weight, in an MDA-MB-231 mouse xenograft model.
WARNING This product is not for human or veterinary use.
1. Discovery of novel potent covalent glutathione peroxidase 4 inhibitors as highly selective ferroptosis inducers for the treatment of triple-